Advanced solid tumors including non-small cell lung cancer (NSCLC), mesothelioma, pancreatic adenocarcinoma, head and neck carcinoma, ovarian cancer, cervical carcinoma, uterine carcinoma and breast cancer.

• Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors Ended
  2022-502867-39-00 1 2023-09-29

Showing 1–1 of 1 trials